Business
Myriad Genetics Highlights Latest Oncology Portfolio Advancements and New Data at ASCO 2023
SALT LAKE CITY, June 01, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will be
About this update from Myriad Genetics, Inc.
[{"type":"text","content":"SALT LAKE CITY, June 01, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will be highlighting new studies and the recent expansion of its Precise™ Oncology Solutions portfolio at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting from June 2-6, 2023. Myriad has recently made several advancements supporting its oncology footprint including hiring oncology experts to its leadership team as well as the addition of the Folate Receptor Alpha (FRα) biomarker to its oncology portfolio. “Our portfolio addition further expands upon our industry-leading suite of solutions spanning biomarker, germline and somatic testing options to support patients with cancer wherever they are on their treatment path,” said Michael Lyons, general manager of oncology, Myriad Genetics. “We are not only enhancing our testing capabilities, but we are also strengthening our expertise. We recently added new team members, including Adam Brufsky, MD, PhD, FACP, who will help us continue to advance our portfolio and vision for precision oncology and patient care.” During ASCO, the following data from Myriad will be presented: Polygenic risk score calibration and association with breast cancer in diverse ancestries (Abstract #10505)Session type: Oral abstract sessionDate: Monday, June 5, 2023 Time: 3:00-6:00 p.m. CDTDescription: In this study of more than 200,000 women, the polygenic risk score (PRS) was well-calibrated and accurately predicted breast cancer risk for women. Incorporation of PRS adds independent information to breast cancer risk models and supports equitable access to personalized risk management. Predicting absolute benefit in risk of metastasis of androgen deprivation therapy added to radiation therapy in patients with newly diagnosed prostate cancer using Prolaris (Abstract #5030)Session type: Poster sessionDate: Saturday, June 3, 2023Time: 8:00-11:00 a.m. CDTDescription: In this cohort of patients spanning all National Comprehensive Cancer Network risk categories, a cell-cycle progression score accurately predicted an individual’s benefit of adding Androgen Deprivation Therapy to Radiation Therapy. “The data we’re sharing at ASCO, along with our contribution of hereditary cancer data to ClinVar, demonstrates our commitment to increasing access to genetic testin...